Finding treatment-resistant depression in real-world data: How a data-driven approach compares with expert-based heuristics

被引:33
|
作者
Cepeda, M. Soledad [1 ]
Reps, Jenna [1 ]
Fife, Daniel [1 ]
Blacketer, Clair [1 ]
Stang, Paul [1 ]
Ryan, Patrick [1 ]
机构
[1] Janssen Res & Dev, Titusville, NJ USA
关键词
databases; decision tree; epidemiology; machine learning; prevalence; NATIONAL COMORBIDITY SURVEY; STAR-ASTERISK-D; MAJOR DEPRESSION; DEFINITION; PREVALENCE; OUTCOMES; EPIDEMIOLOGY; DISORDERS; DATABASES; TRIALS;
D O I
10.1002/da.22705
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Depression that does not respond to antidepressants is treatment-resistant depression (TRD). TRD definitions include assessments of treatment response, dose and duration, and implementing these definitions in claims databases can be challenging. We built a data-driven TRD definition and evaluated its performance. Methods: We included adults with depression, >= 1 antidepressant, and no diagnosis of mania, dementia, or psychosis. Subjects were stratified into those with and without proxy for TRD. Proxies for TRD were electroconvulsive therapy, deep brain, or vagus nerve stimulation. The index date for subjects with proxy for TRD was the procedure date, and for subjects without, the date of a randomly selected visit. We used three databases. We fit decision tree predictive models. We included number of distinct antidepressants, with and without adequate doses and duration, number of antipsychotics and psychotherapies, and expert-based definitions, 3, 6, and 12 months before index date. To assess performance, we calculated area under the curve (AUC) and transportability. Results: We analyzed 33,336 subjects with no proxy for TRD, and 3,566 with the proxy. Number of antidepressants and antipsychotics were selected in all periods. The best model was at 12 months with an AUC = 0.81. The rule transported well and states that a subject with >= 1 antipsychotic or >= 3 antidepressants in the last year has TRD. Applying this rule, 15.8% of subjects treated for depression had TRD. Conclusion: The definition that best discriminates between subjects with and without TRD considers number of distinct antidepressants (>= 3) or antipsychotics (>= 1) in the last year.
引用
收藏
页码:220 / 228
页数:9
相关论文
共 44 条
  • [41] Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data
    Ailawadhi, Sikander
    Cheng, Mu
    Cherepanov, Dasha
    Dersarkissian, Maral
    Stull, Dawn Marie
    Hilts, Annalise
    Chun, Justin
    Duh, Mei Sheng
    Sanchez, Larysa
    CURRENT PROBLEMS IN CANCER, 2024, 50
  • [42] Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry
    Ladoire, Sylvain
    Kamga, Ariane Mamguem
    Galland, Loick
    Desmoulins, Isabelle
    Mayeur, Didier
    Kaderbhai, Coureche
    Ilie, Silvia Mihaelia
    Hennequin, Audrey
    Jankowski, Clementine
    Albuisson, Juliette
    Nambot, Sophie
    Coutant, Charles
    Arnould, Laurent
    Reda, Manon
    Truntzer, Caroline
    Dabakuyo, Sandrine
    BREAST, 2024, 78
  • [43] Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data
    Chan, Henry
    Chai, Kern
    Shih, Steven
    Lewsey, Rebecca
    Chen, Kevin
    McDiarmid, Bridgett
    Jackson, Sharon
    Simpson, David
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (04) : 470 - 477
  • [44] Individual treatment effects of sodium-glucose co-transporter-2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real-world data
    Siriyotha, Sukanya
    Lukkunaprasit, Thitiya
    Looareesuwan, Panu
    Kunakorntham, Patratorn
    Anothaisintawee, Thunyarat
    Nimitphong, Hataikarn
    Mckay, Gareth J.
    Attia, John
    Thakkinstian, Ammarin
    DIABETES OBESITY & METABOLISM, 2024, 26 (10) : 4418 - 4428